Caribou Biosciences Raises $30M to Expand Its Gene-Editing Technology

May 17, 2016

Biotech startup Caribou Biosciences has raised $30 million in funding for its gene-editing technology.

New investors that participated in the Series B round include Anterra Capital, Heritage Group, Maverick Capital Ventures and Pontifax AgTech. They joined existing investors F-Prime Capital Partners, Novartis, Mission Bay Capital and 5 Prime Ventures.

Philip Austin, founding partner at Anterra Capital, joined Caribou’s board of directors with the investment. The company has raised $44.46 million to date.

CEO Rachel Haurwitz co-founded the Berkeley-based startup in 2011 to develop cellular engineering solutions based on CRISPR technologies. Short for “clustered regularly interspaced short palindromic repeats,” CRISPR technologies can edit genetic mistakes and could lead to advances in agricultural biotechnology, industrial biotechnology and curing human diseases.  

"We are delighted to have the support of such an esteemed group of new and current investors, and view the caliber of the participants as further validation of the potential of our CRISPR-Cas genome engineering platform to transform the development of new medical therapies and bio-based products," Haurwitz said in a press release. "We look forward to working with this outstanding group of investors, and bringing their deep expertise and guidance to bear as we deliver on the promise of our technology platform."

The company said it will use the new funds to continue to expand its gene-editing technology platform and accelerate efforts in promising application areas.